Abstract: The present disclosure relates to a method of treating or preventing a disease or disorder selected from the group consisting of a central nervous system disorder, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, a chronic granulomatous disorder, a polycystic ovary syndrome, a thyroid carcinoma, a thyroid autoimmune disorder, a pituitary adenoma, atherosclerosis, hypertension, a skin disease, an inflammation and autoimmune disease, an inflammatory respiratory disease, and a mitochondrial disease by administering 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione or a salt thereof to a subject in need thereof. The disclosure also relates to 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione for use in a pharmaceutical composition or in the manufacture of a medicament for the treatment or prevention of a mitochondrial disease.

Abstract: A process for making a liquid low-sodium food-grade salt (100), wherein a mixture (20) contains water (1), sodium chloride (2) at an amount set between 14% and 26% by weight, alimentary acceptable anions (4) selected among carbonate, iodate, acetate, ascorbate, citrate, propionate, tartrate and sorbate ions at a concentration between 0.1% and 5% by weight. This reduce the electrostatic forces between sodium ions and chloride ions, increasing the ionic mobility with respect to a solution containing the same amount of NaCl only. This increases the tastefulness of the mixture, i.e. it provides a stronger perception of the salty taste by a subject. Moreover, the mixture can undergo to diffusion (17) of a gas (7), which increases kinetic energy and, therefore, further increases ionic mobility.

Abstract: A method for diagnosing and/or evaluating dementia severity in a subject suspected of having or having dementia is provided the method comprising: a) obtaining a test cell sample from the subject, b) assaying the test cell sample to determine a telomere organization signature of the test sample, the telomere organization signature comprising one or more parameters selected from: i) telomere aggregates; ii) telomere number; iii) telomere length and telomere number; iv) telomere aggregates, telomere length and telomere numbers; c) comparing the test cell sample telomere organization signature to a control or one or more predetermined reference signatures; and d) diagnosing whether the subject has dementia and/or the dementia severity according to the test sample telomere organization signature.

Abstract: A method of diagnosing Alzheimer's disease and/or dementia in a subject comprising: a) determining and/or characterizing the telomeric organization of cells in a test sample from the subject; wherein a difference in the telomeric organization, for example the number and/or length of telomeres in the test sample cells compared to a control is indicative the subject has Alzheimer's disease and/or dementia or an increased risk of developing Alzheimer's disease and/or dementia.

Abstract: A method for diagnosing and/or evaluating dementia severity in a subject suspected of having or having dementia is provided the method comprising: a) obtaining a test cell sample from the subject, b) assaying the test cell sample to determine a telomere organization signature of the test sample, the telomere organization signature comprising one or more parameters selected from: i) telomere aggregates; ii) telomere number; iii) telomere length and telomere number; iv) telomere aggregates, telomere length and telomere numbers; c) comparing the test cell sample telomere organization signature to a control or one or more predetermined reference signatures; and d) diagnosing whether the subject has dementia and/or the dementia severity according to the test sample telomere organization signature.

Abstract: A method of diagnosing Alzheimer's disease in a subject comprising: a) determining and/or characterizing the telomeric organization of cells in a test sample from the subject; wherein a difference in the telomeric organization, for example the number and/or length of telomeres in the test sample cells compared to a control is indicative the subject has Alzheimer's disease or an increased risk of developing Alzheimer's disease.